BioCentury
ARTICLE | Company News

NICE backs Novartis' Entresto

April 27, 2016 1:14 AM UTC

The U.K.'s NICE issued draft guidance recommending heart failure drug Entresto sacubitril/valsartan from Novartis AG (NYSE:NVS; SIX:NOVN). The drug is recommended for patients with moderate to very severe symptoms with reduced ejection fraction, and whose heart failure is not controlled by angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs).

NICE estimated Entresto will cost L1,200 ($1,729) annually. The committee said the most plausible incremental cost-effectiveness ratio (ICER) of about L30,000 ($43,236) per quality-adjusted life year (QALY) is a cost-effective use of NHS resources. The European Commission approved Entresto in November. ...